keyword
MENU ▼
Read by QxMD icon Read
search

Disease-modifying antirheumatic drugs

keyword
https://www.readbyqxmd.com/read/29342473/effectiveness-of-early-adalimumab-therapy-in-psoriatic-arthritis-patients-from-reuma-pt-early-psa
#1
Helena Santos, Mónica Eusébio, Joana Borges, Diana Gonçalves, Pedro Ávila-Ribeiro, Daniela Santos Faria, Carina Lopes, João Rovisco, Ana Águeda, Patrícia Nero, Paula Valente, Ana Rita Cravo, Maria José Santos
Objective To compare outcomes in psoriatic arthritis (PsA) patients initiating adalimumab (ADA), with short- and long-term disease duration and to evaluate the potential effect of concomitant conventional synthetic disease-modifying antirheumatic drugs (csDMARD) or glucocorticoids. Methods Analyses included adult PsA patients registered in the Rheumatic Diseases Portuguese Register (Reuma.pt) between June 2008-June 2016 who received ADA for ≥3 months. Psoriatic Arthritis Response Criteria (PsARC) response, tender and swollen joint count, inflammatory parameters, patient (PtGA) and physician global assessment (PhGA), Disease Activity Score-28 joints (DAS28), and Health Assessment Questionnaire Disability Index (HAQ-DI) were compared between patients with <5 years of disease (early PsA) and those with ≥5 years of disease duration (late PsA)...
October 2017: Acta Reumatológica Portuguesa
https://www.readbyqxmd.com/read/29336187/efficacy-and-safety-of-sirukumab-in-japanese-patients-with-moderate-to-severe-rheumatoid-arthritis-inadequately-controlled-by-disease-modifying-anti-rheumatic-drugs-subgroup-analysis-of-a-phase-3-study
#2
Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Masayoshi Harigai, Toshikazu Nakano, Koshiro Akagi, Yoshifumi Ukyo, Benjamin Hsu
Objective To evaluate the efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis uncontrolled by disease modifying antirheumatic drugs. Methods This subgroup analysis based on a double-blind, placebo-controlled, 52-week phase 3 study (SIRROUND-D) assessed American College of Rheumatology (ACR)20 response at week 16 and van der Heijde-modified Sharp score (vdH-S) at week 52 (coprimary endpoints). Results A total of 168 (Japanese)/1670 patients received sirukumab 50 mg/4 weeks (q4w, n = 58), 100 mg/every 2 weeks (q2w, n = 54), or placebo (n = 56) subcutaneously...
January 16, 2018: Modern Rheumatology
https://www.readbyqxmd.com/read/29335350/epidemiology-and-medication-pattern-change-of-psoriatic-diseases-in-taiwan-from-2000-to-2013-a-nationwide-population-based-cohort-study
#3
James Cheng-Chung Wei, Lin-Hong Shi, Jing-Yang Huang, Xue-Fen Wu, Rui Wu, Jeng-Yuan Chiou
OBJECTIVE: To analyze the trend of prevalence and incidence rates for psoriatic arthritis (PsA) and psoriasis in Taiwan, and to determine the changes in medication patterns. METHODS: Data were collected from the Taiwan National Health Insurance Research Database, which covered at least 95% of the population from 2000 to 2013. International Classification of Diseases, 9th edition (ICD-9) was used to identify PsA (ICD-9 696.0) and other psoriasis (ICD-9 696.1). Medications were identified by Anatomical Therapeutic Chemical Classification code...
January 15, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29335344/can-ultrasound-be-used-to-predict-loss-of-remission-in-patients-with-ra-in-a-real-life-setting-a-multicenter-cohort-study
#4
Pascal Zufferey, Almut Scherer, Michael J Nissen, Adrian Ciurea, Giorgio Tamborrini, Laure Brulhart, Sandra Blumhardt, Martin Toniolo, Burkhard Möller, Hans-Ruedi Ziswiler
OBJECTIVE: Several studies have suggested that patients with rheumatoid arthritis (RA) presenting with ultrasound (US) synovitis despite clinical remission have more subsequent flares than those who show both clinical and sonographic remission. The objective of our study was to investigate whether these results could be translated to a real-life setting. METHODS: We compared the time from the first US performed in clinical remission to loss of remission (defined by a DAS28 > 2...
January 15, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29330755/-lymphoma-in-rheumatic-diseases
#5
REVIEW
A Rubbert-Roth, J T Bittenbring, G Assmann
Various systemic inflammatory diseases, such as rheumatoid arthritis (RA), Sjögren's syndrome and systemic lupus erythematosus (SLE) are associated with an increased risk for the development of lymphomas. Studies on patients with RA and Sjögren's syndrome have shown that there is a clear association of the incidence of lymphoma with the severity and activity of the disease and lymphomas in particular are diseases which preferentially occur in immunosuppressed patients; therefore, knowledge of the different lymphoma subtypes, their prognosis and treatment options are important for rheumatologists...
October 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/29329602/abatacept-used-in-combination-with-non-methotrexate-disease-modifying-antirheumatic-drugs-a-descriptive-analysis-of-data-from-interventional-trials-and-the-real-world-setting
#6
Rieke Alten, Harald Burkhardt, Eugen Feist, Klaus Krüger, Juergen Rech, Andrea Rubbert-Roth, Reinhard E Voll, Yedid Elbez, Christiane Rauch
BACKGROUND: Methotrexate (MTX) remains the anchor drug in rheumatoid arthritis (RA) treatment, but is poorly tolerated or contraindicated in some patients. There is a wealth of data supporting the use of abatacept in combination with MTX, but data on alternative conventional synthetic disease-modifying antirheumatic drug (csDMARD) combinations with abatacept are scarce. METHODS: In this post-hoc exploratory analysis, efficacy and safety data were extracted from abatacept RA studies in which combination with csDMARDs other than MTX was permitted: three interventional trials (ATTAIN, ASSURE, and ARRIVE) and one real-world study (ACTION)...
January 2, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29327104/long-term-efficacy-of-spa-therapy-in-patients-with-rheumatoid-arthritis
#7
Mine Karagülle, Sinan Kardeş, Müfit Zeki Karagülle
Our previous crossover randomized trial suggested that spa therapy added to usual pharmacotherapy provides benefits that lasted 6 months over pharmacotherapy alone in rheumatoid arthritis patients. We now extend, and report the long-term results of that study. In the crossover trial, patients were randomized to spa therapy first group or control first group (first assignment, period 1, 6 months); after this period and washout phase (9 months), they crossed over to the other arm (second assignment, period 2, 6 months)...
January 11, 2018: Rheumatology International
https://www.readbyqxmd.com/read/29325724/rheumatoid-arthritis-disease-modifying-agents-and-periprosthetic-joint-infection-what-does-a-joint-surgeon-need-to-know
#8
REVIEW
Mehrnoush H Yeganeh, Michael M Kheir, Alisina Shahi, Javad Parvizi
The incidence of periprosthetic joint infection (PJI) among patients with rheumatoid arthritis (RA) is 1.6× greater than in patients undergoing the same procedure for osteoarthritis. This higher risk "may" be due to the immunosuppressive therapies for RA patients including corticosteroids, such as prednisone, and disease-modifying antirheumatic drugs (DMARDs), such as methotrexate. There is a debate about the role of DMARDs in increasing the incidence of subsequent PJI. Studies show conflicting results, with some demonstrating no significant increase in the rates of PJI and some finding otherwise...
November 23, 2017: Journal of Arthroplasty
https://www.readbyqxmd.com/read/29322372/examination-of-patient-reported-outcomes-in-association-with-tnf-inhibitor-treatment-response-results-from-a-us-observational-cohort-study
#9
Cynthia J Larmore, Natalie N Boytsov, Carol L Gaich, Xiang Zhang, Andre B Araujo, Sabrina Rebello, Bob A Salim, George W Reed, Leslie R Harrold
INTRODUCTION: Implementation of a treat-to-target strategy is challenging when the patient and physician prioritize different goals. This study aimed to "translate" improvements in Clinical Disease Activity Index (CDAI) to concepts that resonate with patients (such as pain, fatigue, morning stiffness) by examining the association between changes in disease activity and patient-reported outcomes (PROs) in a national cohort of patients with rheumatoid arthritis (RA) initiating their first biologic treatment...
January 10, 2018: Rheumatology and Therapy
https://www.readbyqxmd.com/read/29314645/tofacitinib-with-conventional-synthetic-disease-modifying-antirheumatic-drugs-in-chinese-patients-with-rheumatoid-arthritis-patient-reported-outcomes-from-a-phase-3-randomized-controlled-trial
#10
Zhanguo Li, Yuan An, Houheng Su, Xiangpei Li, Jianhua Xu, Yi Zheng, Guiye Li, Kenneth Kwok, Lisy Wang, Qizhe Wu
AIM: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assess the effect of tofacitinib + conventional synthetic disease-modifying anti rheumatic drugs (csDMARDs) on patient-reported outcomes in Chinese patients with RA and inadequate response to DMARDs. METHODS: This analysis of data from the Phase 3 study ORAL Sync included Chinese patients randomized 4 : 4 : 1 : 1 to receive tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, placebo→tofacitinib 5 mg twice daily, or placebo→tofacitinib 10 mg twice daily, with csDMARDs...
January 4, 2018: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29302829/effectiveness-and-safety-of-ustekinumab-in-na%C3%A3-ve-or-tnf-inhibitors-failure-psoriatic-arthritis-patients-a-24-month-prospective-multicentric-study
#11
Maria Sole Chimenti, Augusta Ortolan, Mariagrazia Lorenzin, Paola Triggianese, Marina Talamonti, Luisa Costa, Francesco Caso, Marta Favero, Miriam Teoli, Marco Galluzzo, Raffaele Scarpa, Leonardo Punzi, Roberto Perricone, Roberta Ramonda
The current prospective observational study aimed to evaluate the long-term (24 months), real-life effectiveness of ustekinumab in psoriatic arthritis (PsA). Consecutive patients with moderate-severe PsA and active psoriasis who begun ustekinumab treatment were evaluated prospectively (January 2015-March 2017). Clinimetric scores and biochemical values were assessed at baseline (T0), at 6 (T6), 12 (T12), and 24 (T24) months. Friedman test and generalized linear models were used to compare variables over time...
January 4, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29298452/have-the-annual-trends-of-total-knee-arthroplasty-in-rheumatoid-arthritis-patients-changed
#12
Matthew A Harb, Max Solow, Jared M Newman, Nipun Sodhi, Robert Pivec, Jaiben George, Assem A Sultan, Anton Khlopas, Neil V Shah, Martin W Roche, Michael A Mont
As the use of disease modifying antirheumatic drugs have increased, it remains unclear whether or not this has affected the rates of total knee arthroplasty (TKA) in rheumatoid arthritis (RA) patients. Therefore, the purpose of this study was to evaluate the annual trends of RA patients who underwent TKA. Specifically, we evaluated: (1) the annual trends of TKAs due to RA in the United States population; and (2) the annual trends in the proportion of TKAs due to RA in the United States. The Nationwide Inpatient Sample was used to identify all patients who underwent TKA between 2002 and 2013 (n = 6,492,873)...
January 3, 2018: Journal of Knee Surgery
https://www.readbyqxmd.com/read/29298160/myeloablative-autologous-stem-cell-transplantation-for-severe-scleroderma
#13
RANDOMIZED CONTROLLED TRIAL
Keith M Sullivan, Ellen A Goldmuntz, Lynette Keyes-Elstein, Peter A McSweeney, Ashley Pinckney, Beverly Welch, Maureen D Mayes, Richard A Nash, Leslie J Crofford, Barry Eggleston, Sharon Castina, Linda M Griffith, Julia S Goldstein, Dennis Wallace, Oana Craciunescu, Dinesh Khanna, Rodney J Folz, Jonathan Goldin, E William St Clair, James R Seibold, Kristine Phillips, Shin Mineishi, Robert W Simms, Karen Ballen, Mark H Wener, George E Georges, Shelly Heimfeld, Chitra Hosing, Stephen Forman, Suzanne Kafaja, Richard M Silver, Leroy Griffing, Jan Storek, Sharon LeClercq, Richard Brasington, Mary E Csuka, Christopher Bredeson, Carolyn Keever-Taylor, Robyn T Domsic, M Bashar Kahaleh, Thomas Medsger, Daniel E Furst
BACKGROUND: Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly infusions of cyclophosphamide in patients with scleroderma. METHODS: We randomly assigned adults (18 to 69 years of age) with severe scleroderma to undergo myeloablative autologous stem-cell transplantation (36 participants) or to receive cyclophosphamide (39 participants)...
January 4, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29290762/an-autumn-tale-geriatric-rheumatoid-arthritis
#14
REVIEW
Senol Kobak, Cemal Bes
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by erosive arthritis and systemic organ involvement. The disease may affect all ages and both sexes; usually it is seen in young women aged 25-45. Recent studies have shown that RA is among the most common inflammatory disease in older age groups. While elderly-onset rheumatoid arthritis (EORA) is still discussed in the literature, it is generally accepted as a disease beginning after 65 years of age. Compared with young-onset rheumatoid arthritis (YORA), it was found that EORA had different characteristics...
January 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29290168/the-economic-burden-of-acpa-positive-status-among-patients-with-rheumatoid-arthritis
#15
Jason Shafrin, Mahlet Gizaw Tebeka, Kwanza Price, Chad Patel, Kaleb Michaud
BACKGROUND: Anticitrullinated protein antibodies (ACPAs) are serological biomarkers associated with early, rapidly progressing rheumatoid arthritis (RA), including more severe disease and joint damage. ACPA testing has become a routine tool for RA diagnosis and prognosis. Furthermore, treatment efficacy has been shown to vary by ACPA-positive status. However, it is not clear if the economic burden of patients with RA varies by ACPA status. OBJECTIVE: To determine if the economic burden of RA varies by patient ACPA status...
January 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29290076/risk-of-serious-infections-in-biological-treatment-of-patients-with-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-a-meta-analysis
#16
Sen Wang, Qian He, Zongwen Shuai
The objective of the study is to quantitatively assess the risk of serious infections in patients with axial spondyloarthritis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) treated by biologics enrolled in randomized controlled trials (RCTs). A systematic literature searches of MEDLINE (via PubMed), EMBASE, the Cochrane Library and abstracts archives of the annual scientific meetings of both the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) was conducted through October 2015...
December 30, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29289700/adherence-to-synthetic-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-results-of-the-observar-study
#17
Antonio Juan Mas, Santos Castañeda, José I Cantero Santamaría, José L Baquero, Francisco J Del Toro Santos
BACKGROUND: Treatment compliance with disease-modifying antirheumatic drugs (DMARD) is essential to achieve the therapeutic goals in rheumatoid arthritis (RA). However, despite the need for good compliance, there is evidence that patients with RA frequently fail to use DMARD for the control of RA. Thus, the main objective of the OBSERVAR study is to evaluate the reasons for the lack of therapeutic adherence to synthetic DMARD in these patients. PATIENTS AND METHODS: A Delphi process involving 18 randomly selected Spanish rheumatologists determined the level of agreement with 66 causes of noncompliance selected from the literature in relation to synthetic DMARD in RA...
December 27, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/29288176/do-biological-disease-modifying-antirheumatic-drugs-reduce-the-spinal-fracture-risk-related-to-ankylosing-spondylitis-a-longitudinal-multiregistry-matched-cohort-study
#18
Yohan Robinson, Claes Olerud, Johan Willander
OBJECTIVES: Ankylosing spondylitis (AS) is associated with an increased spinal fracture risk due to the loss of elasticity in spinal motion segments. With the introduction of biological disease-modifying antirheumatic drug (bDMARD) treatment for AS, the individual course of the disease has been ameliorated. This study aims to examine the association of bDMARD treatment and risk of spinal fracture. DESIGN: Longitudinal population-based multiregistry observational matched cohort study...
December 28, 2017: BMJ Open
https://www.readbyqxmd.com/read/29287749/phase-1b-study-of-the-safety-pharmacokinetics-and-disease-related-outcomes-of-the-matrix-metalloproteinase-9-inhibitor-andecaliximab-in-patients-with-rheumatoid-arthritis
#19
David L Gossage, Blanka Cieslarová, Sophe Ap, Hao Zheng, Yan Xin, Preeti Lal, Guang Chen, Victoria Smith, John S Sundy
PURPOSE: Andecaliximab (GS-5745) is a highly selective monoclonal antibody against matrix metalloproteinase-9 (MMP9), a proteolytic enzyme implicated in the pathogenesis of rheumatoid arthritis (RA). This study assessed the safety and pharmacokinetic (PK) parameters of andecaliximab in patients with RA and evaluated the effects of andecaliximab treatment on exploratory disease biomarkers. METHODS: In this double-blind, Phase 1b trial, patients with active RA were randomized (4:1) to receive 400-mg andecaliximab or placebo every 2 weeks for a total of 3 intravenous infusions...
December 26, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29280011/high-burden-of-adverse-events-is-associated-with-reduced-remission-rates-in-early-rheumatoid-arthritis
#20
Laura Kuusalo, Kari Puolakka, Hannu Kautiainen, Anna Karjalainen, Timo Malmi, Leena Paimela, Marjatta Leirisalo-Repo, Vappu Rantalaiho
Adverse events (AEs) are common during disease-modifying antirheumatic drug (DMARD) treatment, but their influence on treatment results is unclear. We studied AEs in relation to disease activity in early rheumatoid arthritis (RA). Ninety-nine patients started intensive treatment with three conventional synthetic DMARDs (csDMARDs) and oral prednisolone, and were randomized to a 6-month induction treatment with infliximab or placebo. All AEs during the first 12 months of treatment were recorded. We scored each AE based on severity (scale 1-4) and defined the burden of AEs as the sum of these scores...
December 26, 2017: Clinical Rheumatology
keyword
keyword
116670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"